| Followers | 26 |
| Posts | 2781 |
| Boards Moderated | 0 |
| Alias Born | 03/18/2013 |
Tuesday, February 28, 2017 1:26:23 PM
Resting Zebra and Zuman;
I filed for Medicare in October 2016, 2 months prior to my 65th Birthday, so I'm good as far as making the deadline. Been ignoring the Invoices. Today, I just mailed my check to the Gubmint for $487.50, for the privilege of being on Medicare.... go figure after working since 12 yrs old, first W-2 I filed when I was 14 yrs.
Hopefully, this fee isn't a yearly fee.... if so, then WFT am I getting Medicare for then? I still pay Obamacare fees for my daughter. I wonder how much the penalty is for not filing? All I can say is this better be worth it..... I'll feel better when I can get my Vascepa script at a discount.
Liked the CC: Thanks to all of you who paraphrased the details of the CC:; Cash Flow Neutral (Good), Revenues $130M (Good), street likes to see increasing Revenues and Scripts. Thanks JL, I agree Primary Endpoint is a lock, just going for the Secondary Endpoints, IMHO those will be also. Just a feeling I have. Be patient my friends.
Nuke
I filed for Medicare in October 2016, 2 months prior to my 65th Birthday, so I'm good as far as making the deadline. Been ignoring the Invoices. Today, I just mailed my check to the Gubmint for $487.50, for the privilege of being on Medicare.... go figure after working since 12 yrs old, first W-2 I filed when I was 14 yrs.
Hopefully, this fee isn't a yearly fee.... if so, then WFT am I getting Medicare for then? I still pay Obamacare fees for my daughter. I wonder how much the penalty is for not filing? All I can say is this better be worth it..... I'll feel better when I can get my Vascepa script at a discount.
Liked the CC: Thanks to all of you who paraphrased the details of the CC:; Cash Flow Neutral (Good), Revenues $130M (Good), street likes to see increasing Revenues and Scripts. Thanks JL, I agree Primary Endpoint is a lock, just going for the Secondary Endpoints, IMHO those will be also. Just a feeling I have. Be patient my friends.
Nuke
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
